Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company, has focused their efforts acquiring, developing and commercializing proprietary products that meet the needs of patients treated by gastroenterologists or primary care physicians. The company is currently commercializing ZEGERID® Capsules and Powder for Oral Suspension to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). For further information, visit the Company’s web site at www.santarus.com.
- 17 years ago
QualityStocks
Santarus, Inc. (NASDAQ: SNTS)
Tags Rodman & Renshaw
Related Post
-
Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ): Positioned at the Center of U.S. Copper Security and Policy
The White House’s recent proclamation targets copper imports with tariffs to bolster domestic production and…
-
SuperCom Ltd. (NASDAQ: SPCB) Expands U.S. Footprint with New Wisconsin Project, 12th State in One Year
SuperCom has secured a new electronic monitoring project with a sheriff’s department in Wisconsin, marking…
-
FDA Guidance Sets Lantern Pharma Inc. (NASDAQ: LTRN) On a Path Toward Realizing Its Clinical Trial Plans for Rare Pediatric Cancer Therapy
Texas-based clinical-stage biotechnology company Lantern Pharma Inc. is developing a number of clinical trials, using…